PL2061810T3 - Sposoby i kompozycje do leczenia neuropatii zależnych od przeciwciał - Google Patents

Sposoby i kompozycje do leczenia neuropatii zależnych od przeciwciał

Info

Publication number
PL2061810T3
PL2061810T3 PL07837788T PL07837788T PL2061810T3 PL 2061810 T3 PL2061810 T3 PL 2061810T3 PL 07837788 T PL07837788 T PL 07837788T PL 07837788 T PL07837788 T PL 07837788T PL 2061810 T3 PL2061810 T3 PL 2061810T3
Authority
PL
Poland
Prior art keywords
compositions
treatment
methods
antibody mediated
mediated neuropathies
Prior art date
Application number
PL07837788T
Other languages
English (en)
Inventor
Susan Halstead
Hugh Willison
Russell P Rother
Original Assignee
Alexion Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alexion Pharma Inc filed Critical Alexion Pharma Inc
Publication of PL2061810T3 publication Critical patent/PL2061810T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Ophthalmology & Optometry (AREA)
  • Oncology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Rheumatology (AREA)
  • Biotechnology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PL07837788T 2006-09-05 2007-09-05 Sposoby i kompozycje do leczenia neuropatii zależnych od przeciwciał PL2061810T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US84229606P 2006-09-05 2006-09-05
EP07837788.4A EP2061810B1 (en) 2006-09-05 2007-09-05 Methods and compositions for the treatment of antibody mediated neuropathies
PCT/US2007/019416 WO2008030505A2 (en) 2006-09-05 2007-09-05 Methods and compositions for the treatment of antibody mediated neuropathies

Publications (1)

Publication Number Publication Date
PL2061810T3 true PL2061810T3 (pl) 2015-05-29

Family

ID=39157834

Family Applications (1)

Application Number Title Priority Date Filing Date
PL07837788T PL2061810T3 (pl) 2006-09-05 2007-09-05 Sposoby i kompozycje do leczenia neuropatii zależnych od przeciwciał

Country Status (17)

Country Link
US (1) US9388235B2 (pl)
EP (4) EP2061810B1 (pl)
JP (2) JP5695317B2 (pl)
KR (1) KR101503540B1 (pl)
AU (1) AU2007293013B2 (pl)
BR (1) BRPI0715869A2 (pl)
CA (1) CA2662480C (pl)
DK (1) DK2061810T3 (pl)
ES (2) ES2616204T3 (pl)
HK (1) HK1126793A1 (pl)
IL (1) IL197148A (pl)
MX (1) MX2009002426A (pl)
NZ (1) NZ575018A (pl)
PL (1) PL2061810T3 (pl)
PT (1) PT2061810E (pl)
SI (1) SI2061810T1 (pl)
WO (1) WO2008030505A2 (pl)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI2359834T1 (sl) 2006-03-15 2017-02-28 Alexion Pharmaceuticals, Inc. Zdravljenje pacientov,ki imajo paroksizmalno nočno hemoglobinurijo, z zaviralcem komplementa
GB0617734D0 (en) 2006-09-08 2006-10-18 Evolutec Ltd Method of treating peripheral nerve disorders
EP2342559A4 (en) * 2008-10-21 2014-12-03 Thomas M Donndelinger METHODS AND COMPOSITIONS FOR PREVENTING ARTIFACTS IN TISSUE SAMPLES
DK2817329T3 (en) 2012-02-20 2019-04-01 Swedish Orphan Biovitrum Ab Publ Polypeptides Binding to Human Complement Component C5.
JP6538561B2 (ja) 2012-10-25 2019-07-03 バイオベラティブ・ユーエスエイ・インコーポレイテッド 抗補体Ｃ１ｓ抗体とそれらの用途
CA2889197A1 (en) 2012-11-02 2014-05-08 True North Therapeutics, Inc. Anti-complement c1s antibodies and uses thereof
EP2996722A4 (en) * 2013-05-15 2017-01-11 Annexon, Inc. Methods of treatment for guillain-barre syndrome
MX2015017341A (es) 2013-07-09 2016-07-06 Anexxon Inc Anticuerpos anti-factor del complemento c1q y uso de los mismos.
CN106103461B (zh) 2014-03-13 2019-05-10 巴塞尔大学 结合抗髓鞘相关糖蛋白的IgM抗体的碳水化合物配体
JP6951246B2 (ja) 2014-11-05 2021-10-20 アネクソン，インコーポレーテッド ヒト化抗補体因子Ｃ１ｑ抗体及びその使用
PL3233912T3 (pl) * 2014-12-19 2021-12-27 Regenesance B.V. Przeciwciała, które wiążą ludzkie c6 oraz ich zastosowania
EP3280440B1 (en) 2015-04-06 2022-11-16 Bioverativ USA Inc. Humanized anti-c1s antibodies and methods of use thereof
AU2016323377B2 (en) 2015-09-16 2021-04-15 Universität Basel Carbohydrate ligands that bind to antibodies against glycoepitopes of glycosphingolipids
SG11201803703UA (en) 2015-11-24 2018-06-28 Annexon Inc Anti-complement factor c1q fab fragments and uses thereof
AU2017283470B2 (en) 2016-06-14 2024-03-21 Regeneron Pharmaceuticals, Inc. Anti-C5 antibodies and uses thereof
JP2021506241A (ja) 2017-12-13 2021-02-22 リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． 抗ｃ５抗体組み合わせ物およびその使用
JP2022508952A (ja) * 2018-10-22 2022-01-19 ラ ファーマシューティカルズ インコーポレイテッド ジルコプランによる神経疾患治療
GB2584105B (en) * 2019-05-21 2023-08-02 Argenx Bvba Methods of treating neuropathy
TW202404632A (zh) * 2022-04-04 2024-02-01 瑞士商赫孚孟拉羅股份公司 用於藉由使用抗ｃ５抗體克羅伐單抗治療或預防格林－巴利症候群之劑量及投予方案

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
US6548640B1 (en) 1986-03-27 2003-04-15 Btg International Limited Altered antibodies
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5260203A (en) 1986-09-02 1993-11-09 Enzon, Inc. Single polypeptide chain binding molecules
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5135916A (en) 1989-06-12 1992-08-04 Oklahoma Medical Research Foundation Inhibition of complement mediated inflammatory response
US5705732A (en) * 1989-06-12 1998-01-06 Oklahoma Medical Research Foundation Universal donor cells
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
AU9149791A (en) 1990-12-06 1992-07-08 T Cell Sciences, Inc. Synergistic compositions of soluble complement receptors and compounds that inhibit complement and/or suppress immune activity
US6407213B1 (en) 1991-06-14 2002-06-18 Genentech, Inc. Method for making humanized antibodies
US5565332A (en) 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
US6025165A (en) 1991-11-25 2000-02-15 Enzon, Inc. Methods for producing multivalent antigen-binding proteins
AU3178993A (en) 1991-11-25 1993-06-28 Enzon, Inc. Multivalent antigen-binding proteins
US5456909A (en) 1992-08-07 1995-10-10 T Cell Sciences, Inc. Glycoform fractions of recombinant soluble complement receptor 1 (sCR1) having extended half-lives in vivo
ATE243745T1 (de) 1994-01-31 2003-07-15 Univ Boston Bibliotheken aus polyklonalen antikörpern
US6074642A (en) 1994-05-02 2000-06-13 Alexion Pharmaceuticals, Inc. Use of antibodies specific to human complement component C5 for the treatment of glomerulonephritis
JP3971797B2 (ja) 1994-09-23 2007-09-05 アレクション・ファーマシューティカルズ・インク 炎症性関節疾患の治療方法
US6685940B2 (en) 1995-07-27 2004-02-03 Genentech, Inc. Protein formulation
US6991790B1 (en) 1997-06-13 2006-01-31 Genentech, Inc. Antibody formulation
US6503947B1 (en) * 1998-01-27 2003-01-07 Brigham And Women's Hospital Method of treating cytotoxic damage
EP1152759A2 (en) * 1999-02-09 2001-11-14 3-Dimensional Pharmaceuticals, Inc. METHODS OF TREATING C1s-MEDIATED DISEASES AND CONDITIONS, AND COMPOUNDS AND COMPOSITIONS THEREFOR
WO2002030985A2 (en) 2000-10-10 2002-04-18 Tanox, Inc. Inhibition of complement c5 activation for the treatment and prevention of delayed xenograft or acute vascular rejection
US20030133939A1 (en) 2001-01-17 2003-07-17 Genecraft, Inc. Binding domain-immunoglobulin fusion proteins
US7432356B2 (en) * 2001-08-17 2008-10-07 Genentech, Inc. Complement pathway inhibitors binding to C5 and C5a without preventing formation of C5b
US7425618B2 (en) 2002-06-14 2008-09-16 Medimmune, Inc. Stabilized anti-respiratory syncytial virus (RSV) antibody formulations
ITMI20021527A1 (it) * 2002-07-11 2004-01-12 Consiglio Nazionale Ricerche Anticorpi anti componente c5 del complemento e loro uso
JP4836451B2 (ja) 2002-07-18 2011-12-14 メルス ベー ヴェー 抗体混合物の組換え生産
AU2003265361A1 (en) 2002-08-28 2004-03-19 Pharmacia Corporation Stable ph optimized formulation of a modified antibody
JP2006516636A (ja) 2003-01-30 2006-07-06 メディミューン，インコーポレーテッド 抗インテグリンαｖβ３抗体製剤及びその用途
SI2335725T1 (sl) 2003-04-04 2017-01-31 Genentech, Inc. Visokokoncentrirane formulacije protiteles in proteinov
US20050019326A1 (en) * 2003-06-16 2005-01-27 The Brigham And Women's Hospital, Inc. C1q complement inhibitors and methods of use thereof
US7482376B2 (en) * 2003-07-03 2009-01-27 3-Dimensional Pharmaceuticals, Inc. Conjugated complement cascade inhibitors
EP1739078A1 (de) * 2005-05-30 2007-01-03 Jerini AG C5a-Rezeptor-Antagonisten
CN101437501B (zh) 2006-03-02 2012-09-05 阿莱克申药物公司 通过抑制补体活性延长同种异体移植物的存活

Also Published As

Publication number Publication date
ES2616204T3 (es) 2017-06-09
EP2380907A1 (en) 2011-10-26
IL197148A0 (en) 2011-08-01
WO2008030505A8 (en) 2009-03-05
KR101503540B1 (ko) 2015-03-17
SI2061810T1 (sl) 2015-04-30
CA2662480A1 (en) 2008-03-13
WO2008030505A2 (en) 2008-03-13
AU2007293013B2 (en) 2013-06-27
EP3199549A1 (en) 2017-08-02
EP2913342A1 (en) 2015-09-02
AU2007293013A1 (en) 2008-03-13
JP2014240438A (ja) 2014-12-25
JP5695317B2 (ja) 2015-04-01
ES2530428T3 (es) 2015-03-02
IL197148A (en) 2016-06-30
PT2061810E (pt) 2015-02-05
MX2009002426A (es) 2009-03-20
DK2061810T3 (en) 2015-02-16
KR20090051063A (ko) 2009-05-20
EP2061810A2 (en) 2009-05-27
WO2008030505A3 (en) 2008-06-19
US9388235B2 (en) 2016-07-12
NZ575018A (en) 2012-04-27
JP2010502708A (ja) 2010-01-28
CA2662480C (en) 2016-11-08
HK1126793A1 (en) 2009-09-11
EP2061810B1 (en) 2014-11-12
US20100143343A1 (en) 2010-06-10
BRPI0715869A2 (pt) 2013-07-30
EP2380907B1 (en) 2016-11-30

Similar Documents

Publication Publication Date Title
IL197148A0 (en) Methods and compositions for the treatment of antibody mediated neuropathies
HK1134679A1 (zh) 用於治療感染的組合物和方法
PL2546253T3 (pl) Podstawione dihydropirazolony do leczenia schorzeń sercowo-naczyniowych i hematologicznych
EP2361089A4 (en) COMPOSITIONS AND METHODS FOR THE TREATMENT OF ALTERED FUNCTION OF -SYNUCLEINE
ZA200900388B (en) Compositions and methods for the treatment of mucositis
IL181896A0 (en) Methods and compositions for the treatment of hyperlipidemia
EP2124985A4 (en) METHOD AND COMPOSITIONS FOR TREATING NERVOUS ELEMENTS
IL193936A0 (en) Compositions and methods for the treatment of immunoinflammatory disorders
WO2007081751A9 (en) Compositions and methods for the treatment of cancer
EP2049151A4 (en) METHOD AND COMPOSITIONS FOR THE TREATMENT OF CANCER
HK1159498A1 (en) Methods and compositions for the treatment of cancer
AU2007243282A8 (en) Compositions and methods for the treatment of cardiovascular disease
IL195272A0 (en) Methods and compositions for the treatment of viral infections
EP2331123A4 (en) COMPOSITIONS AND METHODS FOR TREATING HEPATITIS C
IL197804A0 (en) Compositions for the trearment of hepatitis c and methods for using compositions for the treatment of hepatitis c
IL196843A0 (en) Compositions and methods for the treatment of radiation proctosigmoitis
GB0718446D0 (en) Compositions and methods for the treatment of infection
IL198723A0 (en) Methods and compositions for therapeutic treatment
ZA200703087B (en) Methods and compositions for the treatment of hyperlipidemia
EP2340027A4 (en) METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER
EP2217238A4 (en) METHOD AND COMPOSITIONS FOR THE TREATMENT OF DISEASES RELATED TO PROTEINURIA
IL189009A0 (en) Methods and compositions for the treatment of neuropathies and related disorders
IL196411A0 (en) Anti-cocaine compositions and treatment
EP2150270A4 (en) METHODS AND COMPOSITIONS FOR TREATING CANCER
GB0601950D0 (en) Compositions and methods of treating diabetes